Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with Imatinib

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-006181-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the rate of major molecular response (MMR) at 12 months after Day 1 initiation of first line treatment with imatinib, in patients randomized at month 3 to treatment with dasatinib 100mg QD or imatinib at any dose, after less than optimal response to 1st line imatinib


Critère d'inclusion

  • Chronic Phase Chronic Myeloid Leukemia